LPC invests in Advanced Cell Technology

Advanced Cell Technology said Thursday that it has secured $30 million from Lincoln Park Capital Fund. Based in Marlborough, Mass., ACT is a biotech firm focused on developing human embryonic stem cell and adult stem cell technology.

PRESS RELEASE

MARLBOROUGH, Mass.–(BUSINESS WIRE)–Advanced Cell Technology, Inc. (“ACT”)(OTCBB:ACTC), a leader in the field of regenerative medicine, today announced that it has entered into a $30 million common stock purchase agreement with Lincoln Park Capital Fund, LLC (“LPC”).

“LPC has been an important partner over the years and we are pleased to continue our relationship with them. This facility gives us an additional option in funding the progress of our business, without creating complications in our capital structure. Securing this new line of funding enables us to make prudent decisions and will help us optimize future financing opportunities as we develop our plan to up-list to a national exchange and pursue long-term, fundamental-based, institutional capital,” said Ted Myles, ACT’s Interim President, Chief Operating Officer and Chief Financial Officer.

Under the terms of the purchase agreement, ACT has agreed to file a registration statement with the U.S. Securities & Exchange Commission (“SEC”) covering the shares that may be issued to LPC under the agreement. After the SEC has declared effective the registration statement related to the transaction, the Company has the right over a 36-month period to sell up to $30,000,000 worth of shares of the Company’s Common Stock to LPC, subject to certain limitations and conditions set forth in the agreement. In consideration for entering into the agreement, the Company issued LPC shares of the Company’s Common Stock as a commitment fee.

Dr. Paul K. Wotton, incoming President and CEO of ACT, commented, “This commitment from LPC is a good instrument to have in place as we prepare to initiate our Phase 2 trials for age-related macular degeneration and Stargardt’s macular degeneration. Having this line in place will allow us to bridge in the short-term, and will also play an important strategic role in the longer-term, as we evaluate and prioritize the many exciting programs in our pre-clinical pipeline. I look forward to joining at this pivotal period for ACT and we are pleased to have partners like LPC, to enable us to focus on the rigorous execution of all elements of our business plan.”

The elements of the new arrangement with LPC include:
ACT controls the timing and amount of any sales of common stock to LPC at a known price;
LPC cannot require ACT to make sales, but is obligated to make purchases as ACT directs in accordance with the terms of the agreement;
There is no upper limit on the price per share that LPC could be obligated to pay for shares of common stock under the agreement; and
There are no limitations on use of proceeds, financial covenants, restrictions on future financings, rights of first refusal, participation rights, penalties or liquidated damages.
More information is available in ACT’s Current Report on Form 8-K, filed today with the SEC.

About Advanced Cell Technology, Inc.
Advanced Cell Technology, Inc., (ACT) is a Marlborough, Mass.-based biotechnology company focused on the development and commercialization of human embryonic stem cell (hESC) and adult stem cell technology. The company’s most advanced products are in clinical trials for the treatment of dry age-related macular degeneration, Stargardt’s macular degeneration and myopic macular degeneration. ACT’s preclinical programs involve cell therapies for the treatment of other ocular disorders and for diseases outside the field of ophthalmology, including autoimmune, inflammatory and wound healing-related disorders. The company’s intellectual property portfolio includes pluripotent stem cell platforms – hESC and induced pluripotent stem cell (iPSC) – and other cell therapy research programs. For more information, visit www.advancedcell.com.

About Lincoln Park Capital Fund, LLC (“LPC”)
LPC is a Chicago-based Investment Group and Asset Management Firm focused on opportunistic investing in public and private companies, real estate and high alpha money management strategies. LPC believes that opportunistic investing and long term thinking go hand in hand and strives to make investments that align incentives and lead to long term mutually beneficial relationships. We base our investment decisions on our fundamental analysis, due diligence process and experience. We make investments with a long-term focus knowing that economic, business, and market cycles demand that investors be patient.

Related Posts

Leave a Reply

PEHUB Community

Join the 12503 members of peHUB to make connections, share your opinion, and follow your favorite authors.

Join the Community

Look Who’s Tweeting

Psst! Got any hot tips?

  • This field is for validation purposes and should be left unchanged.

PE HUB News Briefs

RSS Feed Widget

Marketplace

VCJ Headlines (subscribers only)

RSS Feed Widget

Buyouts Headlines (subscribers only)

RSS Feed Widget

Reuters VC and PE feed

RSS Feed Widget